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PURPOSE: Human papillomavirus (HPV) type 16 is one of the major etiologic factors of cervical cancer. Our study
aims to investigate thepotentiality of the antiviral clustered regularly interspacedshort palindromic repeat (CRISPR)/CRISPR-
associated Cas9 system (CRISPR/Cas9) targeting the E6 and E7 oncogenes of HPV16 as a potential chemosensitizer of
cisplatin (cis-diaminedichloroplatinum II; CDDP) for cervical cancer. METHODS: Specifically, the therapeutic efficacy of
combinationofCDDPandHPV16E6+E7-CRISPR/Cas9wasassessed incervical cancercells andcervical cancer xenograft
models. RESULTS: In vitro experiments showed that long-term exposure of SiHa cells to the HPV16 E6+ E7-CRISPR/Cas9
induced apoptosis, and its pro-apoptosis effect becamemore obviouswhen combinedwith CDDP. In vivo study found the
efficacy of the combination of HPV16 E6+E7-CRISPR/Cas9 and CDDPwere superior to either of the treatments in term of
apoptosis induction and metastasis inhibition. CONCLUSION: Collectively, our results suggested that HPV16 E6 + E7-
CRISPR/Cas9 could be an effective sensitizer of CDDP chemotherapy in cervical cancer.
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Cervical cancer is one of the most common types of gynecological
malignancies worldwide. There are 450,000 new cases and
approximately 233,000 deaths per year caused by cervical cancer.
Infection with high-risk human papillomaviruses (HPV), such as type
16 and 18, is a major cause of cervical cancer [1–4].
The E6 and E7 proteins encoded by HPV play major roles in the
development and maintenance of malignancy in cervical cancer [5,6].
The E6 viral oncoprotein binds to wide-type tumor suppressor p53,
while E7 binds to the retinoblastoma (RB) family of tumor suppressor
proteins and disrupts RB/E2F complexes, thereby driving cell
division. Therefore, the E6 and E7 oncogenes represent ideal targets
for gene therapy of cervical cancer.
In previous studies, RNAi technique is used to inhibit gene
expression involved in various human diseases. Several therapeutic
strategies including the application of shRNAs targeting E6 oncogene
presented inhibitory effect on cervical cancer cell growth [7,8].Recently, CRISPR/Cas9 has been developed as a novel therapeutic
strategy and has entered into clinical trials [9]. As the first report of
inhibition of tumor growth derived from cervical cancer cells with a
mixture of CRISPR/Cas9 targeting HPV gene [10], we demonstrate
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targeting the E6, E7-transcript can effectively, specifically and stably
suppress E6 and E7 expression in cervical cancer and inhibit the
cancer cell growth. These results suggest that CRISPR/Cas9 targeting
HPV key oncogenes as a new strategy for cervical cancer and other
HPV-associated cancer therapy.
CDDP is one of the commonly used first-line chemotherapy agents
for various cancers. CDDP-based chemotherapy is an important
treatment option for patients with unresectable recurrent or
metastatic cervical cancer [11,12]. CDDP inhibits HPV E6/E7
expression [13], and allows p53 to escape from E6-mediated
degradation, thereby leading to the accumulation of p53 in the
nucleoli of HeLa cells to induce apoptosis [14]. Combination of
CDDP and radiotherapy restores p53 function and enhances the
radiosensitivity of HPV-16-positive SiHa cells [15]. Unfortunately,
the severe side effects limit the clinical use of high-dose CDDP, and
the development of resistance poses another major obstacle for
long-term use of CDDP [16,17]. Establishment of new therapeutic
strategies either sensitizing cancer cell to CDDP or relieving the side
effects of CDDP will undoubtedly benefit cancer patients.
Here, we test the ability of HPV16 E6/E7-CRISPR/Cas9 to
sensitize HPV16 positive cervical cancer cell SiHa to CDDP in vitro
and in vivo, and find that long-term combinatory exposure to E6 +
E7- CRISPR/Cas9 and CDDP exert synergistic cytotoxicity and
antitumor effects both on SiHa cells and in xenograft mouse models
of cervical cancer.
Material and Methods
Plasmids
The hCas9 expression vector was a gift from Xingxu Huang
(Addgene plasmid # 44,758) [18], and gRNA cloning vectors was a
gift from George Church (Addgene plasmid # 41,824) [19]. The
plasmids were prepared by using the Qiagen Endofree Plasmid Kit
(Qiagen; Hilden, Germany).
Construction of gRNA Expression Plasmids
gRNA expression plasmids were constructed according to
manufacturer's protocol [10]. Briefly, to prepare a 100-bp dsDNA
insert fragment containing the target sequence (20 bp) and a
protospacer-adjacent motif (PAM) sequence, we used a set of
oligonucleotides and generated the fragment using T4 PNK (NEB;
Ipswich, MA, USA). The dsDNA fragments were purified and
inserted into the BbsI site of a gRNA cloning vector with T4 DNA
ligase (NEB; Ipswich, MA, USA). Detailed BLAST searching of
human and murine genomes was carried out to identify potential off
target binding of HPV gRNAs. Two sets of oligonucleotides were
designed. All oligonucleotides were synthesized and purified by
Sangon Biotech Co. (Shanghai, China). The sgRNAs specific to
HPV16 E6 gene were 5′-CACCGCAACAGTTACTGCGACG
TG-3′, and 5′-AAACCACGTCGCAG TAACTGTTGC-3′. The
sgRNAs specific to HPV16 E7 gene were 5′-CACCGACACGTAGA
CATTCGTACTT-3′, and 5′-AAACAAGTACGAAT GTCTAC
GTGT-3′ [10].
Cell Culture and Transfection
The human cervical cancer cell lines SiHa and C33-A were used.
SiHa cells contain a single copy of HPV16 integrated in the
chromosome and express the E6 and E7 oncogenes [20], whereas
C33-A cells were negative for HPV. Cells were maintained inDulbecco's modified Eagle's minimal essential medium (DMEM),
supplemented with 10% fetal calf serum (Hyclone; Logan, UT, USA)
at 37°C in a humidified atmosphere containing 5%CO2. SiHa cells
were seeded into 6-well plates and grew until 60% to 80%
confluency, after which they were transfected with 1 μg of hCas9
expression vector and 1 μg of gRNA expression vector using
Lipofectamine2000 (Invitrogen; Carlsbad, CA, USA) according
to the manufacturer's instructions. Cells were harvested two days
after transfection.
CDDP Treatment and Combinatory Treatment with
CRISPR/Cas9 Transfection
CDDP was obtained from Sigma-Aldrich (St. Louis, MO, USA).
For CDDP + CRISPR/Cas9 combination treatment, cells were
exposed to CRISIR/Cas9 and subsequently exposed to CDDP after
washing with phosphate buffered saline (PBS).
Real-Time RT-PCR
For quantitative real-time RT-PCR, SiHa cells were transfected
with CRISPR/Cas9 as previously described. Total RNA was extracted
with TRIzol reagent (Invitrogen; Carlsbad, CA, USA), the mRNA
expression of E6 and E7 was determined by RT-PCR [21]. GAPDH
was used as an internal reference. The PCR primers were as follows,
E6 forward, 5′-AATGTTTCAGGACCCACAGG-3′; E6 reverse,
5′-TCAGGACACAGTGGCTTTTG-3′; E7 forward, 5′-ATGCAT
GGAGATACACCTACATTGC-3′; E7 reverse, 5′-ACAATTCCTA
GTGTGCCCAT TAACA-3′. In total, three independent experi-
ments were performed.
Western Blot
Western blotting was performed as previously described [10].
Primary antibodies used were mouse monoclonal anti-p53 and
anti-GAPDH, and goat polyclonal anti-p21 (SantaCruz Biotechnologies;
Santa Cruz, CA, USA). GAPDHwas used as internal control for protein
loading and analysis.
Flow Cytometry Analysis
After single-agent or combination therapy, apoptotic cells were
stained with Annexin V-fluorescence isothiocyanate (FITC) and
propidium iodide (PharMingen; San Diego, CA, USA) according to
the manufacturer's instructions and apoptotic cells were quantified by
flow cytometry. All experiments were performed in triplicate, and
repeated three times.
In Vivo Xenografts
Pathogen-free female BALB/C nude mice (aged 4–5 week, SPF
grade and weighing 18–20 g) were purchased from the center of
experimental animal, the Academy of Military Medical Science
(Beijing, China). All animal experiments and protocols were
performed strictly in accordance with the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health. The
animals were kept and the experiments were performed in accordance
with committee's criteria for the care and use of laboratory animals.
Approval for animal experiments was obtained from the institutional
animal welfare committee.
SiHa cells (1×107) in 0.2 ml of serum-free medium were injected
subcutaneously into the right flanks of the mice. Three weeks after the
injection of the cells, mice were randomly divided into four groups
(eight mice per group): the empty vector group, CDDP-treated
group, E6 + E7-treated group, E6/E7-CRISPR/Cas9-treated group.
Figure 1. The specificity and activity on cell proliferation of HPV16-E6/
E7- CRISPR/Cas9. Transfection of HPV-16-E6/E7-CRISPR/Cas9 did not
affect proliferation of HPV-negative C33-A cervical cancer cells, while
the proliferation was severely inhibited by transfection of either
HPV-16-E6-CRISPR/Cas9 or HPV-16-E7-CRISPR/Cas9. The figures
are representativeof three independentexperiments.Data represent the
meanof three impendent experiments±SE. The asterisk represents
statistically significant difference compared with negative control
(*P b .05; **P b .01).
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hydrodynamic tail vein injection method [22]. Briefly, 40 μg Cas9 and 20
μg E6-gRNA and/or 20 μg E7-gRNA, dissolved in 1.5 ml Ringer's
solution (147 mMNaCl, 4 mM KCl and 1.13 mMCaCl2), were rapidly
injected into the tail vein. On the day after the CRISPR/Cas9 injection,
CDDP (4 mg/kg body weight) was intraperitoneally injected. In animals
treated with CDDP alone, CDDP was intraperitoneally injected every
7-day intervals. In addition, tumor size was measured with digital calipers
and volumeswere calculated as length ×width ×height.Micewere killed on
day 21 (day 0was set as the first injection occurred), and the tumor samples
were evaluated by real time PCR, western blot, and flow cytometry.
Statistical Analysis
The statistical significance between groups was determined by
the Mann–Whitney U test. P b .05 was considered statistically
significant. All statistical analyses were performed using the SPSS
software (SPSS, Chicago, IL, USA).Figure 2. Cytotoxic effect of single or combinatory treatment of
with negative control cells, HPV16 E6/E7-CRISPR/Cas9 exerted mos
CDDP was strengthened when combinedwith HPV16 E6/E7-CRISPR/C
The asterisk represents statistically significant difference compared wResults
Inhibition of HPV16 E6 and E7 Expression by CRISPR/Cas9
HPV16 E6- and E7-CRISPR/Cas9 were transfected into
SiHa cells to examine the knocking down efficiency. Real-time
RT-PCR showed that E6-CRISPR/Cas9 knocked down HPV16-E6
and -E7 genes expression by about eight times relative to
negative control, which was similar to the results in our previous
article [10]. These recombinant plasmids were then used in the
following experiments.
The Anti-Viability Effect of HPV16 E6/E7-CRISPR/Cas9
HPV16 E6- and E7-CRISPR/Cas9 was transfected into HPV16
positive (SiHa) and HPV16 negative (C33-A) cancer cells,
respectively, to observe its effect on cell viability. As shown in Figure 1,
both HPV16 E6- and E7-CRISPR/Cas9 severely compromised viability
of SiHa cells, while they had minor effect on C33A cell viability. These
results suggested that HPV16 E6- and E7-CRISPR/Cas9 exerted specific
anti-viability activity on HPV16 positive cells.
Cytotoxicity of HPV16 E6/E7- CRISPR/Cas9 and In Vitro
Synergistic Effect of HPV16 E6/E7-CRISPR/Cas9 and CDDP
According to conventional gynecologic practice, 33 μM of
CDDP could strongly reduce HPV16 E6 oncogene expression in
HPV-positive cancer cells [13], this concentration of CDDP was
therefore used in the following experiments. To assess the
cytotoxicity of HPV16 E6/E7 CRISPR/Cas9, SiHa cells were
exposed to HPV16 E6/E7 CRISPR/Cas9 and 33 μM of CDDP for
7 days, respectively. As shown in Figure 2, the most outstanding
cytotoxicity was observed in cells transfected by E6 + E7 CRISPR/
Cas9 among other treatments. The additive cytotoxicity of HPV16
E6/E7 CRISPR/Cas9 and CDDP was further examined, by which
cells were exposed to 33 μM of CDDP for 4 days followed by
HPV16 E6/E7-CRISPR/Cas9 transfections on subsequent days.
Cells exposed to CDDP combined with E6 + E7-CRISPR/Cas9
suffered the most significant cell growth inhibition compared
to cells exposed to CDDP alone. Of note, short-term (less
than 3 days) exposure of SiHa cells to CDDP combined with
HPV16 E6/E7 CRISPR/Cas9 exhibited no synergistic cytotoxicity
(data not shown).CDDP, HPV16 E6/E7-CRISPR/Cas9 on SiHa cells. (A) Compared
t significant cytotoxic effect on SiHa cells. (B) The cytotoxicity of
as9. Data represent themean of three impendent experiments ± SE.
ith negative control (*P b .05; **P b .01).
Figure 3. The effect of CDDP andHPV16 E6/E7-CRISPR/Cas9 on cell apoptosis and recovery. (A)Western blot results showed that HPV16E6/
E7-CRISPR/Cas9 caused the most significant increase of P53 and P21 expression.(B) Cell recovery assay showed that CDDP and HPV16 E6/
E7-CRISPR/Cas9 co-treatment most significantly inhibited cell recovery ability. The figures are representative of three independent
experiments. Data represent themean of three impendent experiments ± SE. The asterisk represents statistically significant difference
compared with negative control (*P b .05; **P b .01).
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with CDDP on Apoptosis and Cell Recovery
To assess the effect of CDDP and E6/E7-CRISPR/Cas9 treatment
on cell apoptosis, adherent cells were collected and protein were
extracted after 6-day exposure and the expression of p53 and p21 were
analyzed by western blot. As shown in Figure 3A, apoptotic proteins
P53 and P21 were enhanced in E6 + E7-CRISPR/Cas9-transfected
cells compared with that of CDDP-treated cells.
Cells exposed to long-term (7 days) single or combinatory
treatment of CDDP and E6/E7-CRISPR/Cas9 were subsequently
incubated for 7 days in normal media. Cells recovery was most slowFigure 4. Synergistic inhibition of CDDP and HPV16 E6/E7-CRISPR/Ca
day 21 after first injection, tumor were removed and photographed.; (
indicated time points after treatment.(C-D) The total RNA was isolated
by real-time RT-PCR. Data represent the mean of three impendent e
difference compared with negative control (*P b .05; **P b .01).from exposure to HPV16 E6 + E7-CRISPR/Cas9 + CDDP among
other treatment (Figure 3B).
Synergistic Inhibition of In Vivo TumorGrowth by Combination
Therapy with HPV16 E6/E7-CRISPR/Cas9 and CDDP
The inhibitory efficacy of HPV16 E6/E7-CRISPR/Cas9 and
CDDP co-treatment on cervical cancer growth was further examined
in xenograft mice models. Compared with CDDP single treatment,
HPV16 E6/E7-CRISPR/Cas9 and CDDP co-administration significantly
restrained tumor growth as illustrated by much smaller tumor volume in
mice co-treatedwithHPV16E6 +E7 +CDDP(Figure 4A andB). And thes9 co-treatment on xenograft tumor growth. (A) Mice were killed at
B) The volumes of xenograft tumors were measured and plotted at
from tumortissues, and the expression of E6 and E7were detected
xperiments ± SD. The asterisk represents statistically significant
Figure 5. Proapoptotic effect of CDDP combined with HPV16 E6/E7-CRISPR/Cas9 in xenograft tumor tissues. (A) Western blot results
showed that CDDP andHPV16E6/E7-CRISPR/Cas9 co-treated xenograft tumor tissues presented themost significant increase of Bax and P53 and
decrease of Bcl-2. (B) Apoptosis assay by flow cytometry using Annexin V and PI staining showed that CDDP and HPV16 E6/E7-CRISPR/Cas9
cotreatment produced a significant increase in percentage of apoptotic cells. (1, Control-treated; 2 CDDP-treated; 3, E6+E7CRISPR/Cas9-treated;
4, E6 + E7 + CDDP-treated).
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of co-treated mice relative to that of CDDP single treated mice (Figure 4C
andD). These data confirmed that HPV16 E6 + E7-CRISPR/Cas9 could
potentiate the therapeutic efficacy of CDDP for cervical cancer.
The Inhibitory Effect of HPV16 E6/E7-CRISPR/Cas9 and CDDP
Co-Treatment on InVivoCancerCell Apoptosis andLungMetastasis
To elucidate the inhibitory mechanism of HPV16 E6/E7-CRISPR/Cas9
and CDDP co-treatment on xenograft tumor growth, the expression of
apoptosis-associated protein including P53, Bax and Bcl-2 in xenografts was
detected using western blot. Compared to CDDP-treated mice,
pro-apoptosis proteins P53 and Bax were elevated while anti-apoptosis
protein Bcl-2 was reduced in tumor specimens of HPV16 E6/E7-CRISPR/
Cas9 and CDDP co-treated-mice (Figure 5A). And flow cytometry analysis
of xenografts showed a significant increase of apoptotic cells in
tumor specimens of HPV16 E6/E7-CRISPR/Cas9 and CDDP
co-treated-mice relative to CDDP-treated mice (Figure 5B). Finally,
histopathological examination found more atypical nuclei in the lungs
of CDDP -treated-mice than that in the HPV16 E6/E7-CRISPR/Cas9and CDDP co-treated-mice, indicating the enhanced inhibitory effect
of HPV16 E6/E7-CRISPR/Cas9 and CDDP co-treatment on lung
metastasis of cervical cancer cells (Figure 6).
Discussion
Cervical cancer is the second most common cancer in women
worldwide though well-organized screening has been expanded. The
majority of cases are caused by infection of high-risk types of human
papillomaviruses which express the E6 and E7 oncogenes [23,24].
Studies have demonstrated that the expression of these oncogenes is
indispensable for tumor development and maintenance of malignant
phenotypes. Development of novel strategies targeting E6 and E7
oncogenes will be a kind of addition to the current therapeutic arsenal
against cervical cancer with high risk HPV infection.
Recently, CRISPR/Cas9 has been developed as a promising new
tool to suppress gene expression [25,26]. Tumor cells are typically
resistant to growth suppressive signals and apoptosis, and in
HPV-infected cancer cells the viral oncogenes E6 and E7 aggravated
this kind of resistance. In our previous study, CRISPR/Cas9 specific
Figure 6. Analysis of lung metastasis using H&E staining. H&E staining of lung tissue sections from control + CDDP-treated mice (A) and
HPV16 E6 + E7 CRISPR/Cas9 + CDDP-treated mice (B) indicated that HPV16 E6 + E7 CRISPR/Cas9 + CDDP-treatment inhibited lung
metastasis of cervical cancer cells.
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knockdown E6 and E7 expression along with accumulation of p53
and p21 protein, and finally result in remarkably inhibition of
proliferation of cervical cancer in vitro and in vivo. Here, transfection
of HPV16 E6/E7-CRISPR/Cas9 caused significant suppression of
cell growth in HPV16-positive SiHa cervical cancer cells, whereas
they had no effect in HPV-negative C33-A cells, demonstrating the
effectiveness and specificity of these CRISPR/Cas9 systems. CDDP is
the most active anticancer agent available for clinical treatment of
cervical cancer, but its administration is severely hindered by the
occurrence of insensitivity and resistance. We then aimed to investigate
whether HPV16 E6/E7-CRISPR/Cas9 could be used as a CDDP
sensitizer for cervical cancer treatment. In our studies, exposure of cells
to either E6 + E7 specific CRISPR/Cas9 with CDDP significantly
inhibited cell growth in vitro, suggesting that CRISPR/Cas9 targeting
E6 + E7 could function as CDDP-sensitizers. However, short-term
exposure of cervical cancer cells to E6 + E7-CEISPR/Cas9 combined
with CDDP showed no synergistic cytotoxicity. Contrarily, long-term
E6 and E7 gene silence increased the sensitivity of SiHa cells to CDDP
and induced substantial apoptosis. E6 + E7 specific CEISPR/Cas9 was a
more potent sensitizer of CDDP, which was similar to the result of the
superiority of the E6 + E7-specific CEISPR/Cas9 at inducing cellular
senescence. Published data suggested that the functional restoration of
wild-type TP53, which induced the regression of cervical carcinomas,
could be achieved either by inhibition of E6 + E7 expression or by
treatment with CDDP. Therefore, the combination of CDDP and
HPV16 E6/E7-CRISPR/Cas9 might have a synergistic effect on the
restoration of TP53 and be a more effective therapy for cervical cancer
than either treatment alone. This assumption about the chemosensitizing
activity of HPV16 E6 + E7-CRISPR/Cas9 was validated in vitro and
in vivo, and the mechanisms of the synergistic action of HPV16 E6 +
E7-CEISPR/Cas9 and CDDP were at least associated with induction
of apoptosis.
Tumor suppressor p53 is a powerful anti-tumor molecule that is
often inactivated in various cancers [27]. In the present study,
transfection of HPV16 E6 + E7-CRISPR/Cas9 plasmids strongly
increased p53 protein level. P53 promotes cell apoptosis via
transcriptionally activating genes promoting cell death. We found
that the expression of Bax was greatly increased while Bcl-2 wasdiminished along with P53 elevated in vitro and in vivo after
transfection of HPV16 E6 + E7-CRISPR/Cas9 plasmids. Consistent
with these observations, HPV16 E6/E7- CRISPR/Cas9 and CDDP
co-treatment caused robust apoptosis and tumor growth suppression
compared to negative controls.
This is the first report of HPV16 E6/E7-CRISPR/cas9 as an effective
sensitizer for CDDP chemotherapy in cervical cancer. We have
demonstrated that HPV16 E6/E7-CRISPR/Cas9 could effectively and
specifically coordinate with CDDP for HPV16 positive cervical cancer.
Notably, CDDP and HPV16 E6/E7-CRISPR/Cas9 co-treatment could
inhibit lung metastasis of subcutaneous xenograft, while CDDP alone could
not prevent lung dissemination. These results indicated that a combination
therapy involving cisplatin and HPV16 E6/E7-CRISPR/Cas9 could
be advantageous in improving prognosis, which of cervical cancer
patients encouraged further investigation of the potentiality of HPV16
E6/E7-CRISPR/Cas9 as a therapeutic agent for cervical cancer.
In conclusion, we validated the therapeutic synergy of HPV16 E6/E7-
CRISPR/Cas9 and CDDP for HPV16-positive cervical cancer with in
vitro and in vivo study models, promising HPV16 E6/E7-CRISPR/Cas9
as a potential chemosensitizer for CDDP. Further study about associations
and synergies between HPV16 E6/E7-CRISPR/Cas9 and other
chemo-therapeutics will produce new options for cervical cancer treatment
and improve the clinical outcome of cervical cancer patients.
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